I'm not familiar with NORD. The more working on developing improved therapies, the better!

NO LINK AVAILABLE

NORD honors Onyx Pharmaceuticals for development of Kyprolis

Last night in Washington, DC, at its annual gala, the National Organization for Rare Disorders (NORD) -- of which the IMF is a member organization -- recognized Onyx Pharmaceuticals for the development and approval of carfilzomib (Kyprolis) for the treatment of progressive forms of multiple myeloma.

Amyloidosis related presentation important for our readers interested in amyloidosis

Alnylam Pharmaceuticals' CEO Presents at 2013 Bank of America Merrill Lynch Health Care Conference (Transcript)

Onyx Pharmaceuticals is featuring a few more Kyprolis study results at ASCO than Celgene, but many are for blood cancers besides multiple myeloma...

NO LINK AVAILABLE

Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual Meeting

SOUTH SAN FRANCISCO, CA--(Marketwired - May 15, 2013) - Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets, Kyprolis® (carfilzomib) for Injection, and Stivarga® (regorafenib) tablets across a range of cancers. These presentations will take place at the 49th American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, 2013, in Chicago, IL.

"The data being presented at ASCO add to the depth of our understanding of how these medicines work across tumor types and treatment settings," said Pablo Cagnoni, M.D., Executive Vice President, Global Research & Development and Technical Operations at Onyx Pharmaceuticals. "We are committed to exploring therapies in difficult-to-treat cancers for patients who have limited treatment options."
Nexavar® (sorafenib) tablets
 
Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The Phase 3 DECISION trial

• Dr. Marcia Brose, University of Pennsylvania Health System, United States
• Sunday, June 2, 2013
• Oral Presentation: 3:20 - 3:35 p.m., N Hall B1
• Plenary Session - Special Sessions, Core Sessions
• Abstract # 4

Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in > 3000 Sor-treated patients (pts): clinical findings in pts with liver dysfunction

• Dr. Jorge Marrero, University of Michigan, United States
• Sunday, June 2, 2013
• Poster viewing: 8:00 - 11:45 a.m., S Hall A2
• General poster session - Gastrointestinal (Noncolorectal) Cancer
• Abstract # 4126

Kyprolis® (carfilzomib) for Injection
Final results from the Phase 1b/2 study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma

• Dr. Michael Wang, MD Anderson Cancer Center, United States
• Monday, June 3, 2013
• Poster viewing: 1:15 - 5:15 p.m., E450b
• Poster discussion: 4:45 - 5:45 p.m., E354b
• Poster discussion session - Lymphoma and Plasma Cell Disorders, Poster #9
• Abstract # 8529

Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a Phase (Ph) 1/2 trial

• Dr. Cyrille Touzeau, University of Nantes, France
• Monday, June 3, 2013
• Oral Presentation: 9:15 - 9:30 a.m., E Arie Crown Theater
• Oral abstract session - Myeloma
• Abstract # 8513

Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM)

• Dr. Shebli Atrash, University of Arkansas for Medical Sciences, United States
• Sunday, June 2, 2013
• Poster viewing: 8:00 - 11:45 a.m., S Hall A2
• General poster session - Lymphoma and Plasma Cell Disorders
• Abstract # 8595

Results of a Phase 1/2 study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM)

• Dr. James R. Berenson, Institute for Myeloma & Bone Cancer Research, United States
• Sunday, June 2, 2013
• Poster viewing: 8:00 - 11:45 a.m., S Hall A2
• General poster session - Lymphoma and Plasma Cell Disorders
• Abstract # 8599

Results of a Phase 1 trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL)

• Dr. Jennifer Ann Woyach, Ohio State University, United States
• Sunday, June 2, 2013
• Poster viewing: 8:00 - 11:45 a.m., S Hall A2
• General poster session - Leukemia, Myelodysplasia, and Transplantation
• Abstract # 7077

Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up

• Dr. Andrzej J. Jakubowiak, University of Chicago, United States
• Monday, June 3, 2013
• Poster viewing: 1:15 - 5:15 p.m., E450b
• Poster discussion: 4:45 - 5:45 p.m., E354b
• Poster discussion session - Lymphoma and Plasma Cell Disorders, Poster #23
• Abstract # 8543

Stivarga® (regorafenib) tablets
Mutational analysis of plasma DNA from patients (pts) in the Phase 3 GRID study of regorafenib (REG) vs placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: correlating genotype with clinical outcomes

• Dr. George Demetri, Dana-Farber Cancer Institute, United States
• Monday, June 3, 2013
• Oral Presentation: 3:45 - 4:00 p.m., S100bc
• Oral abstract session - Sarcoma
• Abstract # 10503

Results from a Phase 3 trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): subgroup analysis of outcomes based on pretreatment characteristics

• Dr. Heikki Joensuu, Helsinki University Central Hospital, Finland
• Saturday, June 1, 2013
• Poster viewing: 1:15 - 5:00 p.m., S Hall A2
• General poster session - Sarcoma
• Abstract # 10551

Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: an ongoing randomized, double-blind, Phase 3 trial

• Dr. Ann-Lii Cheng, National Taiwan University Hospital, Taipei
• Sunday, June 2, 2013
• Poster viewing: 8:00 - 11:45 a.m., S Hall A2
• General poster session - Gastrointestinal (Noncolorectal) Cancer
• Abstract # TPS4163 (Trials in Progress)

Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the Phase 3 CORRECT study

• Dr. Axel Grothey, Mayo Clinic, United States
• Sunday, June 2, 2013
• Poster viewing: 8:00 - 11:45 a.m., S Hall A2
• General poster session - Gastrointestinal (Colorectal) Cancer
• Abstract # 3637

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): analysis of age subgroups in the Phase 3 CORRECT trial

• Dr. Eric van Cutsem, University Hospital Leuven in Gasthuisberg, Belgium
• Sunday, June 2, 2013
• Poster viewing: 8:00 - 11:45 a.m., S Hall A2
• General poster session - Gastrointestinal (Colorectal) Cancer
• Abstract # 3636

Analysis of plasma protein biomarkers from the CORRECT Phase 3 study of regorafenib for metastatic colorectal cancer

• Dr. Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, United States
• Tuesday, June 4, 2013
• Poster viewing: 8:00 - 12:00 p.m., S405
• Poster discussion: 11:30 - 12:30 p.m., S406
• Poster discussion session - Gastrointestinal (Colorectal) Cancer, Poster #6
• Abstract # 3514

I was surprised by how few presentations were being made at ASCO in June on Celgene's behalf. The warnings were three times as long as the presentation part of the news release...

NO LINK AVAILABLE

MULTIPLE PRESENTATIONS AND POSTERS EVALUATING CELGENE PRODUCTS TO BE HIGHLIGHTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2013 ANNUAL MEETING

Clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials in  approximately 30 posters and presentations evaluating Celgene products in a range ofcancers including pancreatic cancer, multiple myeloma, myelodysplastic syndromes,  and non-Hodgkin’s lymphomas at the American Society of Clinical Oncology 2013 Annual Meeting being held at the McCormick Place in Chicago, IL, from May 31 – June 4, 2013. As part of this collection of abstracts, there are multiple oral presentations, including:

*Times listed are Central Daylight Time

Pancreatic Cancer:

• Abstract #4005 – Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates (Von Hoff, et al.) – Monday, June 3, 11:15 a.m., E Hall D1

Multiple Myeloma:

• Abstract #8509 – Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients (Boccadoro ) – Monday, June 3, 8 a.m., E Arie Crown Theater

• Abstract #8510 - A phase 3, multicenter, randomized, open-label study of pomalidomide (POM) + low-dose dexamethasone (LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM) (San Miguel) – Monday, June 3, 8:15 a.m., E Arie Crown Theater

Myelodysplastic Syndromes:

• Abstract #7002 – A Randomized study of lenalidomide (LEN) +/- erythropoietin (EPO) in RBC transfusion dependent (TD) lower risk myelodysplastic (MDS) without del 5q resistant to EPO– GFM. LenEpo 2008 study (Toma, et al) – Tuesday, June 4, 8:15 a.m., E354b

My last post showed you a snapshot from an untrained writer's point of view. This link takes you to a general article about multiple myeloma and new therapies from a pharmacists point of view. Interesting. Cold, matter of fact. A stark contrast from my last post...

Pharmacist to Pharmacist
Multiple Myeloma: Advances in Treatment Bring Hope

I run across local human interest stories about multiple myeloma patients daily. I usually don't share them with you here. But this one is touching and sheds some light on how our cancer is percieved by the public. Worth a look!

Couple remains hopeful after rare cancer diagnosis

Its not a secret, but money is needed in order to follow-up on all of these new, exciting myeloma therapy ideas. I have written about Senesco Technologies' promising new drug, SNS01-T, a number of times. So this is good news! Looks like Senesco has enough money to keep working on it...

Senesco Announces $1.255 Million Equity Financing

Read more here: http://www.heraldonline.com/2013/05/09/4848642/senesco-announces-1255-million.html#storylink=cpy